Welcome to Cyxone!

Cyxone develops new drugs based upon a natural plant protein

Cyxone AB is a biopharmaceutical company developing drugs based on cyclotides, a natural class of plant proteins, for immune-related diseases. Cyxone’s focus is to bring its drug candidate against MS, T20K, through preclinical studies and phase I clinical trials.

Upcoming events

Mid Small Cap Forum, London

Start date: September 26 2017

End date: September 27 2017

Cyxone will attend the Mid Small Cap Forum in London

Drug Discovery Innovation Programme, Munich

Start date: October 5 2017

End date: October 6 2017

Cyxone will attend the Drug Discovery Innovation Programme in Munich, Germany.

More information about the conference